Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Ribonucleotide reductase inhibition enhances chemoradiosensitivity of human cervical cancers.

Kunos CA, Radivoyevitch T, Pink J, Chiu SM, Stefan T, Jacobberger J, Kinsella TJ.

Radiat Res. 2010 Nov;174(5):574-81. doi: 10.1667/RR2273.1. Epub 2010 Sep 10.

2.

Radiosensitization of human cervical cancer cells by inhibiting ribonucleotide reductase: enhanced radiation response at low-dose rates.

Kunos CA, Colussi VC, Pink J, Radivoyevitch T, Oleinick NL.

Int J Radiat Oncol Biol Phys. 2011 Jul 15;80(4):1198-204. doi: 10.1016/j.ijrobp.2011.01.034. Epub 2011 Apr 4.

3.

Modulating radiation resistance by inhibiting ribonucleotide reductase in cancers with virally or mutationally silenced p53 protein.

Kunos CA, Chiu SM, Pink J, Kinsella TJ.

Radiat Res. 2009 Dec;172(6):666-76. doi: 10.1667/RR1858.1.

4.

Deoxynucleoside salvage facilitates DNA repair during ribonucleotide reductase blockade in human cervical cancers.

Kunos CA, Ferris G, Pyatka N, Pink J, Radivoyevitch T.

Radiat Res. 2011 Oct;176(4):425-33. Epub 2011 Jul 14.

6.

Ribonucleotide reductase inhibition restores platinum-sensitivity in platinum-resistant ovarian cancer: a Gynecologic Oncology Group Study.

Kunos C, Radivoyevitch T, Abdul-Karim FW, Fanning J, Abulafia O, Bonebrake AJ, Usha L.

J Transl Med. 2012 Apr 27;10:79. doi: 10.1186/1479-5876-10-79.

7.

Phase I trial of pelvic radiation, weekly cisplatin, and 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) for locally advanced cervical cancer.

Kunos CA, Waggoner S, von Gruenigen V, Eldermire E, Pink J, Dowlati A, Kinsella TJ.

Clin Cancer Res. 2010 Feb 15;16(4):1298-306. doi: 10.1158/1078-0432.CCR-09-2469. Epub 2010 Feb 9.

8.

Inhibitors of ribonucleotide reductase. Comparative effects of amino- and hydroxy-substituted pyridine-2-carboxaldehyde thiosemicarbazones.

Cory JG, Cory AH, Rappa G, Lorico A, Liu MC, Lin TS, Sartorelli AC.

Biochem Pharmacol. 1994 Jul 19;48(2):335-44.

PMID:
8053929
9.

The synergistic interaction of gemcitabine and cytosine arabinoside with the ribonucleotide reductase inhibitor triapine is schedule dependent.

Sigmond J, Kamphuis JA, Laan AC, Hoebe EK, Bergman AM, Peters GJ.

Biochem Pharmacol. 2007 May 15;73(10):1548-57. Epub 2007 Jan 21.

PMID:
17324380
10.

Reduced level of ribonucleotide reductase R2 subunits increases dependence on homologous recombination repair of cisplatin-induced DNA damage.

Lin ZP, Lee Y, Lin F, Belcourt MF, Li P, Cory JG, Glazer PM, Sartorelli AC.

Mol Pharmacol. 2011 Dec;80(6):1000-12. doi: 10.1124/mol.111.074708. Epub 2011 Aug 29.

11.

In vitro and in vivo radiosensitization induced by the ribonucleotide reductase inhibitor Triapine (3-aminopyridine-2-carboxaldehyde-thiosemicarbazone).

Barker CA, Burgan WE, Carter DJ, Cerna D, Gius D, Hollingshead MG, Camphausen K, Tofilon PJ.

Clin Cancer Res. 2006 May 1;12(9):2912-8.

12.

Elevated ribonucleotide reductase levels associate with suppressed radiochemotherapy response in human cervical cancers.

Kunos CA, Radivoyevitch T, Kresak A, Dawson D, Jacobberger J, Yang B, Abdul-Karim FW.

Int J Gynecol Cancer. 2012 Nov;22(9):1463-9. doi: 10.1097/IGC.0b013e318270577f.

13.

Ribonucleotide reductase inhibition by metal complexes of Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone): a combined experimental and theoretical study.

Popović-Bijelić A, Kowol CR, Lind ME, Luo J, Himo F, Enyedy EA, Arion VB, Gräslund A.

J Inorg Biochem. 2011 Nov;105(11):1422-31. doi: 10.1016/j.jinorgbio.2011.07.003. Epub 2011 Jul 31.

14.

MEK2 regulates ribonucleotide reductase activity through functional interaction with ribonucleotide reductase small subunit p53R2.

Piao C, Youn CK, Jin M, Yoon SP, Chang IY, Lee JH, You HJ.

Cell Cycle. 2012 Sep 1;11(17):3237-49. doi: 10.4161/cc.21591. Epub 2012 Aug 16.

15.

The human ribonucleotide reductase subunit hRRM2 complements p53R2 in response to UV-induced DNA repair in cells with mutant p53.

Zhou B, Liu X, Mo X, Xue L, Darwish D, Qiu W, Shih J, Hwu EB, Luh F, Yen Y.

Cancer Res. 2003 Oct 15;63(20):6583-94.

16.

Overexpression of the R2 subunit of ribonucleotide reductase in human nasopharyngeal cancer cells reduces radiosensitivity.

Kuo ML, Hwang HS, Sosnay PR, Kunugi KA, Kinsella TJ.

Cancer J. 2003 Jul-Aug;9(4):277-85.

PMID:
12967138
17.

Triapine (3-aminopyridine-2-carboxaldehyde- thiosemicarbazone): A potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity.

Finch RA, Liu M, Grill SP, Rose WC, Loomis R, Vasquez KM, Cheng Y, Sartorelli AC.

Biochem Pharmacol. 2000 Apr 15;59(8):983-91.

PMID:
10692563
19.

Yeast Sml1, a protein inhibitor of ribonucleotide reductase.

Chabes A, Domkin V, Thelander L.

J Biol Chem. 1999 Dec 17;274(51):36679-83.

20.

Supplemental Content

Support Center